Lirong Zhang1, Jingjing Zhang2, Lixia Xu2, Zijian Zhuang1, Jingjin Liu2, Suwan Liu2, Yunchao Wu3, Aihua Gong2, Miaomiao Zhang4, Fengyi Du5. 1. Department of Radiology, Affiliated Hospital of Jiangsu University, Zhenjiang, People's Republic of China. 2. School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China. 3. The Third People's Hospital of Changzhou, Changzhou, People's Republic of China. 4. School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China. 1000003928@ujs.edu.cn. 5. School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China. biodfy@ujs.edu.cn.
Abstract
BACKGROUND: Therapeutic tumor vaccine (TTV) that induces tumor-specific immunity has enormous potentials in tumor treatment, but high heterogeneity and poor immunogenicity of tumor seriously impair its clinical efficacy. Herein, a novel NIR responsive tumor vaccine in situ (HA-PDA@IQ/DOX HG) was prepared by integrating hyaluronic acid functionalized polydopamine nanoparticles (HA-PDA NPs) with immune adjuvants (Imiquimod, IQ) and doxorubicin (DOX) into thermal-sensitive hydrogel. RESULTS: HA-PDA@IQ NPs with high photothermal conversion efficiency (41.2%) and T1-relaxation efficiency were using HA as stabilizer by the one-pot oxidative polymerization. Then, HA-PDA@IQ loaded DOX via π-π stacking and mixed with thermal-sensitive hydrogel to form the HA-PDA@IQ/DOX HG. The hydrogel-confined delivery mode endowed HA-PDA@IQ/DOX NPs with multiple photothermal ablation performance once injection upon NIR irradiation due to the prolonged retention in tumor site. More importantly, this mode enabled HA-PDA@IQ/DOX NPs to promote the DC maturation, memory T cells in lymphatic node as well as cytotoxic T lymphocytes in spleen. CONCLUSION: Taken together, the HA-PDA@IQ/DOX HG could be served as a theranostic tumor vaccine for complete photothermal ablation to trigger robust antitumor immune responses.
BACKGROUND: Therapeutic tumor vaccine (TTV) that induces tumor-specific immunity has enormous potentials in tumor treatment, but high heterogeneity and poor immunogenicity of tumor seriously impair its clinical efficacy. Herein, a novel NIR responsive tumor vaccine in situ (HA-PDA@IQ/DOX HG) was prepared by integrating hyaluronic acid functionalized polydopamine nanoparticles (HA-PDA NPs) with immune adjuvants (Imiquimod, IQ) and doxorubicin (DOX) into thermal-sensitive hydrogel. RESULTS:HA-PDA@IQ NPs with high photothermal conversion efficiency (41.2%) and T1-relaxation efficiency were using HA as stabilizer by the one-pot oxidative polymerization. Then, HA-PDA@IQ loaded DOX via π-π stacking and mixed with thermal-sensitive hydrogel to form the HA-PDA@IQ/DOX HG. The hydrogel-confined delivery mode endowed HA-PDA@IQ/DOX NPs with multiple photothermal ablation performance once injection upon NIR irradiation due to the prolonged retention in tumor site. More importantly, this mode enabled HA-PDA@IQ/DOX NPs to promote the DC maturation, memory T cells in lymphatic node as well as cytotoxic T lymphocytes in spleen. CONCLUSION: Taken together, the HA-PDA@IQ/DOX HG could be served as a theranostic tumor vaccine for complete photothermal ablation to trigger robust antitumor immune responses.
Authors: Guozhu Xie; Nikola A Ivica; Bin Jia; Yingzhong Li; Han Dong; Yong Liang; Douglas Brown; Rizwan Romee; Jianzhu Chen Journal: Nat Biomed Eng Date: 2020-10-12 Impact factor: 25.671
Authors: Ajith Ravindran; D Nirmal; Binola K Jebalin I V; K P Pinkymol; P Prajoon; J Ajayan Journal: Opt Quantum Electron Date: 2022-07-26 Impact factor: 2.794